EGFR inhibitors combined with MET tyrosine kinase inhibitors such as SU11274 and PHA665752 or MET antibody such as DN-30 synergistically inhibited cell proliferation and promoted apoptosis in NSCLC (52, 53). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.